348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
In: Annals of Oncology, Jg. 31 (2020-09-01), Heft Supplement 4, S. S386- (2S.)
Online
academicJournal
Zugriff:
Titel: |
348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
|
---|---|
Autor/in / Beteiligte Person: | Eiger, D. ; Maurer, C. ; Brandao, M. ; Aftimos, P.G. ; Punie, K. ; Taylor, D. ; Van den Mooter, T. ; Poncin, R. ; Canon, J L. ; Duhoux, F. ; Casert, V. ; Clatot, F. ; Velghe, C. ; Craciun, L. ; Paesmans, M. ; de Azambuja, E. ; Ignatiadis, M. ; Larsimont, D. ; Piccart, M. ; Buisseret, L. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 31 (2020-09-01), Heft Supplement 4, S. S386- (2S.) |
Veröffentlichung: | 2020 |
Medientyp: | academicJournal |
ISSN: | 0923-7534 (electronic) |
DOI: | 10.1016/j.annonc.2020.08.450 |
Sonstiges: |
|